High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is the most common form of inherited mental retardation, and it is caused in most of cases by epigenetic silencing of the Fmr1 gene. Today, no specific therapy exists for FXS, and current treatments are only directed to improve behavioral symptoms. Neuronal progenitors derived from FXS patient induced pluripotent stem cells (iPSCs) represent a unique model to study the disease and develop assays for large-scale drug discovery screens since they conserve the Fmr1 gene silenced within the disease context. We have established a high-content imaging assay to run a large-scale phenotypic screen aimed to identify compounds that reactivate the silenced Fmr1 gene. A set of 50,000 compounds was tested, including modulators of several epigenetic targets. We describe an integrated drug discovery model comprising iPSC generation, culture scale-up, and quality control and screening with a very sensitive high-content imaging assay assisted by single-cell image analysis and multiparametric data analysis based on machine learning algorithms. The screening identified several compounds that induced a weak expression of fragile X mental retardation protein (FMRP) and thus sets the basis for further large-scale screens to find candidate drugs or targets tackling the underlying mechanism of FXS with potential for therapeutic intervention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They performed a high-content drug screen of 50,000 compounds using neuronal progenitor cells and identified several compounds that induced expression of the fragile X mental retardation protein [52].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [52]
Citations
Cites
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620 · cited 1×
“Neuronal precursors were differentiated from iPSCs by using dual Smad inhibition as described earlier.(21,22) Briefly, 10(5) undifferentiated human iPSCs (hiPSCs) were given to an ultralow attachment 96-well in 0.”
MethodInstability of a 550-Base Pair DNA Segment and Abnormal Methylation in Fragile X Syndrome
Oberlé, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boué, J., Bertheas, M. F., & Mandel, J. L. (1991) · Science · doi:10.1126/science.252.5009.1097 · Cited by 1,499 · cited 1×
“13 probe as described previously.(23) For the PCR amplification of CGG repeats, the AmplideX Fmr1 PCR Kit (Asuragen, Austin, TX) was used with primers flanking the repeats.”
MethodAbnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5401 · Cited by 1,046 · cited 1×
“The Fmr1 knockout mouse shares anatomic and behavioral phenotypes with the human FXS and has contributed to the understanding of the neurobiology of the disease.(7) Although animal models allow the study of behavioral phenotypes,(8) mouse models with CGG repeat expansion knocked into Fmr1 do not methylate and silence…”
BackgroundFmr1 knockout mice: A model to study fragile X mental retardation
THEDUTCHBELGIANFRAGILEXCONSOR (1994) · Cell · doi:10.1016/0092-8674(94)90569-x · Cited by 1,035 · cited 1×
“To study the disease, there are promising although limited animal models.(6) The Fmr1 knockout mouse shares anatomic and behavioral phenotypes with the human FXS and has contributed to the understanding of the neurobiology of the disease.”
BackgroundTherapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711 · cited 1×
“In fact, HDAC inhibitors have been previously shown to induce FMRP expression with modest effects in combination with 5-aza-2′-deoxycytidine treatment.(26,30) Although identifying the mode of action of these hits is beyond the scope of this study, these results validate our assay in a high-throughput format and pave t…”
BackgroundJacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 2×
“high-content screening, fragile X syndrome, induced pluripotent stem cells or the regulation of altered neurologic signaling pathways but do not affect the methylation status of Fmr1.”
BackgroundSelf-citationInduced pluripotent stem cells — opportunities for disease modelling and drug discovery
Grskovic, M., Javaherian, A., Strulovici, B., & Daley, G. Q. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3577 · Cited by 474
Urbach, A., Bar-Nur, O., Daley, G. Q., & Benvenisty, N. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.04.005 · Cited by 407 · cited 1×
“In ESCs, the Fmr1 gene is still expressed in undifferentiated cells and undergoes silencing upon differentiation, whereas in iPSCs, the Fmr1 gene remains silent also before differentiation.(14) Although FXSiPSCs cannot mimic the silencing of Fmr1 that occurs during development, they are an useful model system for stud…”
BackgroundGeneration of human-induced pluripotent stem cells
Park, I.-H., Lerou, P. H., Zhao, R., Huo, H., & Daley, G. Q. (2008) · Nature Protocols · doi:10.1038/nprot.2008.92 · Cited by 402
Yuan, S. H., Martin, J., Elia, J., Flippin, J., Paramban, R. I., Hefferan, M. P., Vidal, J. G., Mu, Y., Killian, R. L., Israel, M. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017540 · Cited by 380
Cited by
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
Machine learning and image-based profiling in drug discovery
Scheeder, C., Heigwer, F., & Boutros, M. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.05.004 · Cited by 169
Human induced pluripotent stem cells for modelling neurodevelopmental disorders
Ardhanareeswaran, K., Mariani, J., Coppola, G., Abyzov, A., & Vaccarino, F. M. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.45 · Cited by 160
Stem Cells, Genome Editing, and the Path to Translational Medicine
Soldner, F., & Jaenisch, R. (2018) · Cell · doi:10.1016/j.cell.2018.09.010 · Cited by 142
Metadata
- Authors
- Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., Mueller, M., Fodor, B. D., & Cobos-Correa, A.
- Affiliations
- Novartis (Switzerland) (CH)
- Venue
- SLAS DISCOVERY
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 20
- Issue
- 9
- Pages
- 1101-1111
- ISSN
- 2472-5552 (ISSN-L)
- OpenAlex
- W1875301382
- Cited by
- 87
- References
- 30
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 9 · 2018: 14 · 2017: 8 · 2016: 19 · 2015: 2
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 2377 d)
- Locations
- SLAS DISCOVERY (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- fragile X syndrome, FMR1 gene silencing, epigenetic silencing, induced pluripotent stem cells, neuronal precursors, phenotypic screening, epigenetic regulators, drug discovery, machine learning, single-cell image analysis
- MeSH terms
- Cells, Cultured, Drug Evaluation, Preclinical, Fragile X Syndrome, Humans, Trinucleotide Repeats, Gene Silencing, Fragile X Messenger Ribonucleoprotein 1, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome. https://app.cochat.ai/papers/10.1177/1087057115588287
- The paper
- Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., Mueller, M., Fodor, B. D., & Cobos-Correa, A. (2015). High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome. SLAS DISCOVERY. https://doi.org/10.1177/1087057115588287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.